Elanco Animal HealthELAN
ELAN
About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Employees: 9,450
0
Funds holding %
of 7,245 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
11% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 126
4% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $10.8M
0.88% more ownership
Funds ownership: 98.98% [Q4 2024] → 99.86% (+0.88%) [Q1 2025]
8% less funds holding
Funds holding: 386 [Q4 2024] → 357 (-29) [Q1 2025]
12% less capital invested
Capital invested by funds: $5.93B [Q4 2024] → $5.19B (-$739M) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
36% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 69
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
5%
downside
Avg. target
$15.40
22%
upside
High target
$19
51%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
Stifel Jonathan Block | 27%upside $16 | Buy Maintained | 19 May 2025 |
Piper Sandler David Westenberg | 5%downside $12 | Neutral Maintained | 6 Mar 2025 |
UBS Andrea Alfonso | 35%upside $17 | Buy Maintained | 26 Feb 2025 |
Morgan Stanley Erin Wright | 3%upside $13 | Equal-Weight Maintained | 26 Feb 2025 |
Barclays Balaji Prasad | 51%upside $19 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 19 articles about ELAN published over the past 30 days
Neutral
PRNewsWire
6 days ago
Elanco to Participate in the Upcoming Investor Conferences
GREENFIELD, Ind. , May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
Neutral
Seeking Alpha
1 week ago
Elanco: Deleveraging Takes Time
Elanco's shares have been pressured due to pipeline delays and debt from the Bayer acquisition, causing cautious optimism despite recent valuation resets. The company focuses on animal health, with balanced pet and livestock products, but struggles with debt and underwhelming growth since acquiring Bayer's animal health business. Despite some sales growth and debt reduction efforts, EBITDA and earnings are declining, limiting enthusiasm for significant investment.
Neutral
Seeking Alpha
2 weeks ago
Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call Transcript
Elanco Animal Health Incorporated (NYSE:ELAN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Tiffany Kanaga - Head of Investor Relations Jeffrey Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Jonathan Block - Stifel Michael Ryskin - Bank of America Andrea Alfonso - UBS Brandon Vazquez - William Blair Ekaterina Knyazkova - JPMorgan Navann Ty - BNP Paribas Mike DiFiore - Evercore ISI Erin Wright - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health First Quarter 2025 Earnings Conference Call.
Neutral
Benzinga
2 weeks ago
Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide
Elanco Animal Health Incorporated ELAN reported first-quarter 2025 adjusted earnings per share of 37 cents. That's up 9% year over year.
Neutral
Zacks Investment Research
2 weeks ago
Compared to Estimates, Elanco Animal Health (ELAN) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Elanco Animal Health (ELAN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Zacks Investment Research
2 weeks ago
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.34 per share a year ago.
Neutral
PRNewsWire
2 weeks ago
Elanco Animal Health Reports First Quarter 2025 Results
Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results: Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growth Reported Net Income of $67 million, Adjusted Net Income of $184 million Adjusted EBITDA of $276 million, or 23.1% of Revenue Reported EPS of $0.13, Adjusted EPS of $0.37 Net leverage ratio of 4.4x Adjusted EBITDA Full Year 2025 Guidance: Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digits Raising 2025 innovation revenue target to $660 to $740 million Reported Net Loss of $(35) to $(7) million, maintaining guidance for Adjusted EBITDA of $830 to $870 million Reported Loss Per Share of $(0.07) to $(0.01), maintaining guidance for Adjusted EPS of $0.80 to $0.86 Outlook incorporates current estimate for tariff net impact of $16 to $20 million to Adjusted EBITDA and expected continued macro volatility, offset by a strong first quarter performance Expecting gross debt paydown of $450 to $500 million in 2025 2025 year-end net leverage ratio target improved to 3.9x to 4.3x, enabled by disciplined working capital management, more favorable foreign exchange rates, and lotilaner U.S. royalty monetization GREENFIELD, Ind. , May 7, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2025, provided guidance for the second quarter of 2025, and updated guidance for the full year 2025.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Positive
Benzinga
2 weeks ago
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
Elanco Animal Health Incorporated ELAN on Monday announced the sale of certain future tiered royalties and commercial milestones associated with Xdemvy (lotilaner ophthalmic solution) 0.25% for the human health application of lotilaner to Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash.
Neutral
PRNewsWire
2 weeks ago
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown
GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash.
Charts implemented using Lightweight Charts™